UNSPSC 51182042: Oxymesterone

This classification denotes an anabolic steroid with the molecular formula C20H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4R73K9MRMX, chemically known as 4,17beta-dihydroxy-17-methylandrost-4-en-3-one but generally known as oxymesterone, which bears US NIH Compound Identifier 72061. European Medicines Agency schedules Oxymesterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09566MIG.

UNSPSC 51182042 Oxymesterone (Commodity) covers anabolic steroid pharmaceuticals, though recent state and local procurement activity under this code focuses on broader generic multi-source pharmaceutical contracting that may encompass this and related products. State and local governments procure controlled pharmaceutical substances through cooperative purchasing vehicles and multi-award contracts managed by state purchasing offices. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a primary issuing body for generic and specialty pharmaceutical procurement at scale, leveraging cooperative purchasing agreements that span multiple states and local government facilities. These solicitations typically involve multiple-award structures where vendors compete on pricing competitiveness (weighted heavily in evaluation), compliance with FDA and Drug Supply Chain Security Act (DSCSA) requirements, EDI capability, administrative fee structures, and current Good Manufacturing Practices (cGMP) certification. Distribution occurs through authorized pharmaceutical wholesalers with established chargeback systems, and vendors must maintain substantial commercial general liability ($5,000,000 per occurrence), network security and privacy liability ($2,000,000), and professional liability ($2,000,000) coverage.

MMCAP's January 2026 RFP for Generic Multi Source Pharmaceuticals and OTC Products (S1070000015802), due March 26, 2026, represents the most recent documented activity under this code. The procurement spans Minnesota and Oregon through the cooperative purchasing vehicle, with awarded vendors effective July 1, 2026, and contract terms of two years for new responders, with optional extensions through June 30, 2028 at MMCAP's discretion. Evaluation weighted price competitiveness at 75 percent, with fixed pricing (10 percent), compliance with administrative data format requirements (5 percent), EDI capability (5 percent), and acceptance of a 3 percent administrative fee (5 percent). Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC) and submit detailed product information including NDC codes, SKUs, UPCs, strength, dosage form, and manufacturing locations through Google Chrome via the ePro system with Excel-to-CSV formatting. No specific set-aside designations or disadvantaged-enterprise restrictions were disclosed in the available solicitation documentation.